



## First Half FY2017 Corporate Update to Shareholders Now Available Online

**Tokyo, Japan and London, United Kingdom – 2 February 2018:** Sosei Group Corporation (“Sosei” or the “Company”; TSE Mothers Index: 4565), the world leader in GPCR medicine design and development, is pleased to announce that the first half FY2017 Corporate Update to Shareholders (*Kabunushi Tsushin*) is now available for download via the Company’s website at [http://www.osei.com/en/ir/library/results\\_briefing.html](http://www.osei.com/en/ir/library/results_briefing.html).

-Ends-

### **About Sosei**

Sosei is an international biopharmaceutical company focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. The Company is advancing a broad and deep pipeline of partnered and wholly owned product candidates in multiple therapeutic areas, including CNS, cancer, metabolic diseases and other rare/specialty indications. The Company’s leading clinical programs include a proprietary Phase 2 candidate for dementia with Lewy bodies (DLB) in Japan, together with partnered candidates aimed at the symptomatic treatment of Alzheimer’s disease (with Allergan) and immuno-oncology approaches to treat cancer (with AstraZeneca). Sosei’s additional partners and collaborators include Novartis, Teva, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys. The Company is headquartered in Japan with R&D facilities in the UK.

Sosei is listed on the Mothers Index of the Tokyo Stock Exchange (ticker: 4565). For more information, please visit <http://www.osei.com/en/>.

### **Contact information**

Chris Cargill, Head of Investor Relations and Corporate Communications  
+44 (0)7912 892 199  
[ccargill@osei.com](mailto:ccargill@osei.com)

Harumi Banse, Corporate Communications (Japan)  
+81 3 5210 3399  
[hbanse@osei.com](mailto:hbanse@osei.com)